Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: A meta-analysis

Pharmacogenetics and Genomics

Volumn 20, Issue 9, 2010, Pages 525-531

  Tang, Hui Lin ^a   Ma, Lu Lin ^b   Xie, Hong Guang ^c,d   Zhang, Ting ^a   Hu, Yong Fang ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

cyclosporine; CYP3A5; kidney transplantation; meta analysis P glycoprotein; pharmacogenetics; pharmacogenomics

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A5; CYCLOSPORIN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ACUTE GRAFT REJECTION; ALLELE; ARTICLE; ASIAN; CAUCASIAN; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY GRAFT; PHARMACOGENOMICS; PRIORITY JOURNAL; ADULT; DOSE RESPONSE; FEMALE; GENETICS; GRAFT REJECTION; HETEROZYGOTE; KIDNEY TRANSPLANTATION; MALE; META ANALYSIS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICS;

ADULT; ALLELES; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HETEROZYGOTE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77955926766     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833ccd56     Document Type: Article

References (49)

1. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43:630-635.
2. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268:6077-6080.
3. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27:201-214.
4. Hesselink DA, Smak Gregoor PJ, Weimar W. The use of cyclosporine in renal transplantation. Transplant Proc 2004; 36:99S-106S.
5. Xie HG. Personalized immunosuppressive therapy in pediatric heart transplantation: progress, pitfalls and promises. Pharmacol Ther 2010; 126:146-158.
6. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) 1 in organ transplantation. Drugs 2001; 61:1957-2016.
7. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999; 68:55-62.
8. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24:330-350. 329.
9. Keown PA. New concepts in cyclosporine monitoring. Curr Opin Nephrol Hypertens 2002; 11:619-629.
10. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci\USA 1987; 84:7735-7738.
11. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40:159-168.
12. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12:121-132.
13. Rosso Felipe C, de Sandes TV, Sampaio EL, Park SI, Silva HT Jr, Medina Pestana JO. Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc 2009; 41:1441-1455.
14. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004; 26:192-199.
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem MS, Chuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.
16. Husert E, Haberl M, Burk O, Wolbold R, He Y, QKlein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.
17. Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba J, KSchuetz EG, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95:1297-1300.
18. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62:162-172.
19. Lamba JK, Lin YS, Shuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294.
20. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5:243-272.
21. Utecht KN, Hiles JJ, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 2006; 63:2340-2348.
22. Saeki M, Saito Y, Nakamura T, Murayama N, Kim SR, Ozawa S, et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 2003; 21:653-660.
23. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54:205-218.
24. Kahan BD, Welsh M, Schoenberg L, Rutzky LP, Katz SM, Urbauer DL, et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62:599-606.
25. Clase CM, Mahalati K, Kiberd BA, Lawen JG, West KA, Fraser AD, et al. Adequate early cyclosporin exposure is critical to prevent allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2:789-795.
26. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-254.
27. Anglicheau D, Thervet E, Etienne I, Hurault DLB, Le Meur Y, Touchard G, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75:422-433.
28. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14:147-154.
29. Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 2004; 14:665-671.
30. Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 2005; 37:178-181.
31. Chu XM, Hao HP,Wang GJ, Guo LQ, Min PQ. Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients. Acta Pharmacol Sin 2006; 27:1504-1508.
32. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 2006; 33:1093-1098.
33. Fredericks S, Jorga A, MacPhee IA, Reboux S, Shiferaw E, Moreton M, et al. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant 2007; 21:252-257.
34. Eng HS, Mohamed Z, Calne R, Lang CC, Mohd MA, Seet WT, et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int 2006; 69:1858-1864.
35. Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc 2008; 40:1690-1695.
36. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, et al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 2008; 64:1069-1084.
37. Chen B, Zhang W, Fang J, Jin Z, Li J, Yu Z, Cai W. Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. Xenobiotica 2009; 39:931-938.
38. Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X, et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur J Clin Pharmacol 2009; 65:239-247.
39. Singh R, Srivastava A, Kapoor R, Sharma KR, Mittal DR. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmaco 2009; 380:169-177.
40. Yates CR, Zhang WH, Song PF, Li S, Gaber AO, Kotb M, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43:555-564.
41. Min DI, Lee M, Ku Y, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000; 68:478-486.
42. Chowbay B, Li HH, David M, Cheung YB, Lee EJ. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2004; 60:159-171.
43. Hu YF, Zhou HH. Contribution of genetic polymorphisms of the CYP3A4, CYP3A5 and MDR1 genes to cyclosporine disposition. Chinese Pharmacol Bull 2005; 21:257-261.
44. Thervet E, Anglicheau D, Legendre C, Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 2008; 30:143-150.
45. Lindholm A, Welsh M, Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetics parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52:359-371.
46. First MR, Schroeder TJ, Monaco AP, Simpson MA, Curtis JJ, Armenti VT. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant 1996; 10:55-59.
47. Hesselink DA, Van Gelder T, Van Schaik RHN, Balk AH, van der Heiden IP, van Dam T, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76:545-556.
48. Jiang ZP, Wang YR, Xu P, Liu RR, Zhao XL, Chen FP, et al. Meta-analysis of the effect of MDRI C3435T polymorphism on cyclosporine pharmacokinetic. Central South Pharmacy 2008; 6:111-116.
49. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7:97-104.